Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 104

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 104
---
876339. doi: 10.3389/fimmu.2022.876339.
3 Kersten MJ, Saevels K, Beguin Y, Vermaat JSP, Verbruggen N, Spoon M, et al. Seven-day vein-to-vein point-of-car manufactured CD19 CAR T-cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 ATALANTA-1 trial. Abstract 2113. Presented at the 2023 ASH Annual Meeting and Expostion; December 9-12,2023: San Diego, CA. Kersten MJ, Saevels K, Willems E, Liefaard MC, Milatos S, Pont MJ, et al. ATLANTA-1: A phase 1/2 trial of GLPG5101, a fresh, stem-like, early memory CD19 CAR T-cell therapy with a 7-day vein-to-vein time, for the treatment of relapsed/refractory non-Hodgkin lymphoma. Abstract 93. Presented at the 2024 ASH Annual Meeting and Exposition; December 7-10,2024: San Diego, CA.
​
Innovation engine to develop next-generation cell therapies
With the 2022 acquisition of U.S.-based AboundBio, we have significantly expanded our capabilities in next-generation cell therapy discovery and development. Our innovation engine is built on the ability to generate vast and diverse human antibody libraries in multiple formats, including antigen-binding fragments (Fab), single-chain variable fragments (scFv), and unique variable heavy (VH) domains. These libraries enable the rapid discovery of high-affinity binders, within days to weeks, that can be optimized for development and adapted for various applications, such as multi-targeting CARs.
Our next-generation cell therapy pipeline provides a strong foundation for sustainable value-creation. It comprises multi-targeting, armored cell therapy constructs designed to improve potency, prevent resistance, and improve persistence of CAR-Ts in hematological and solid tumors. 
We are preparing to initiate clinical development of our first armored, bi-specific CAR-T candidate in 2025, and our goal is to expand our clinical pipeline with at least one new program per year starting in 2026.
By leveraging proprietary methodologies, we enhance binder diversity, affinity, and specificity, increasing the potential for next-generation, multi-targeting, armored cell therapies. These innovations aim to address key limitations